Australia's Cambium Bio advances on signing MoU for Elate Ocular

Cambium Bio

05/09/2025 04:09

** Shares of Australia's Cambium Bio CMB.AX rise as much as 15.8% to A$0.55

** Stock has gained 5.3% so far in the week, on track to record its second consecutive week of gains, if the trend holds

** Regenerative medicine firm signs memorandum of understanding (MoU) with French pharma company Benta SAS

** MoU to establish a strategic partnership for the development and commercialisation of Elate Ocular (CAM-101) for dry eye disease in Europe and the Middle East

** Stock has risen 23.8% this year, as of 0304 GMT

(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com;))